Patents by Inventor Kim Vilbour Andersen
Kim Vilbour Andersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6921657Abstract: The present invention relates to enzymes produced by mutating the genes for a number of subtilases and expressing the mutated genes in suitable hosts are presented. The enzymes exhibit improved wash performance in any detergent in comparison to their wild type parent enzymes.Type: GrantFiled: January 3, 2003Date of Patent: July 26, 2005Assignee: Novozymes A/SInventors: Peter Kamp Hansen, Peter Bauditz, Frank Mikkelsen, Kim Vilbour Andersen
-
Patent number: 6831158Abstract: Polypeptide conjugates with G-CSF activity comprising a polypeptide having at least one introduced lysine residue and at least one removed lysine residue compared to the sequence of human G-CSF, and which are conjugated to 2-6 polyethylene glycol moieties. The conjugates have a low in vitro bioactivity, a long in vivo half-life, a reduced receptor-mediated clearance, and provide a more rapid stimulation of production of white blood cells and neutrophils than non-conjugated recombinant human G-CSF.Type: GrantFiled: July 10, 2002Date of Patent: December 14, 2004Assignee: Maxygen Holdings Ltd.Inventors: Torben Lauesgaard Nissen, Kim Vilbour Andersen, Christian Karsten Hansen, Jan Moller Mikkelsen, Hans Thalsgaard Schambye
-
Publication number: 20040241806Abstract: The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at least one non-polypeptide moiety attached to an attachment group of the polypeptide. The attachment group may e.g., be a lysine, cysteine, aspartic acid or glutamic acid residue or a glycosylation site, and the non-polypeptide moiety may e.g., be a polymer such as polyethylene glycol or an oligosaccharide. The conjugate has one or more improved properties such as increased biological half-life and reduced side effects.Type: ApplicationFiled: November 10, 2003Publication date: December 2, 2004Applicant: Maxygen Holdings, Ltd.Inventors: Torben Lauesgaard Nissen, Kim Vilbour Andersen, Christian Karsten Hansen, Jan Moller Mikkelsen, Hans Thalsgard Schambye
-
Patent number: 6806063Abstract: Conjugates of Factor VII (FVII) and Factor VIIa (FVIIA) are provided, as are methods for preparing them. Methods for producing novel polypeptides contributing to the production of such conjugates are provided. Methods of treatment by administering a FVII or FVIIa conjugate are provided.Type: GrantFiled: February 12, 2001Date of Patent: October 19, 2004Assignees: Maxygen ApS, Maxygen Holdings Ltd.Inventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes
-
Patent number: 6780629Abstract: The present invention relates to subtilase enzymes of the I-S1 and I-S2 sub-groups having an additional amino acid in the active site loop (c) region from positions 125 to 132. The variant subtilases of the present invention exhibit improved wash performance in a detergent in comparison to its parent enzyme.Type: GrantFiled: September 13, 2002Date of Patent: August 24, 2004Assignee: Novozymes A/SInventors: Peter Kamp Hansen, Peter Bauditz, Frank Mikkelsen, Kim Vilbour Andersen, Carsten Andersen, Mads Norregaard-Madsen
-
Patent number: 6773907Abstract: The present invention relates to subtilase enzymes of the I-S1 and I-S2 sub-groups having an additional amino acid in the active site loop (b) region from positions 95 to 103. The variant subtilases of the present invention exhibit improved wash performance in a detergent in comparison to its parent enzyme.Type: GrantFiled: September 12, 2002Date of Patent: August 10, 2004Inventors: Peter Kamp Hansen, Peter Bauditz, Frank Mikkelsen, Kim Vilbour Andersen, Carsten Andersen, Mads Norregaard-Madsen
-
Publication number: 20040013644Abstract: The invention relates to a conjugate exhibiting interferon &bgr; (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.Type: ApplicationFiled: June 27, 2003Publication date: January 22, 2004Applicants: Maxygen ApS, Maxygen Holdings Ltd.Inventors: Poul Baad Rasmussen, Joern Drustrup, Grethe Rasmussen, Anders Hjelholt Pedersen, Hans Thalsgard Schambye, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20040014948Abstract: The invention relates to a single-chain oilgomeric polypeptide antagonist which binds to an extracellular ligand-binding domain of a cellular receptor of a type requiring binding of an oligomeric ligand to two or more receptor subunits to be activated, the polypeptide comprising at least two, typically structurally homologous, receptor-binding sites of which at least one is capable of binding to a ligand-binding domain of the cellular receptor and at least one is incapable of effectively binding to a ligand-binding domain of the cellular receptor, whereby the single-chain oligomeric polypeptide is capable of binding to the receptor, but incapable of activating the receptor; as well as to nucleotide sequences encoding such single-chain oligomeric polypeptides, expression vectors comprising such a nucleotide sequence, recombinant host cells comprising such a nucleotide sequence or expression vector, methods for producing the nucleotide sequences and polypeptides, pharmaceutical compositions comprising the singlType: ApplicationFiled: May 23, 2003Publication date: January 22, 2004Applicant: Maxygen ApSInventors: Torben Halkier, Hans Thalsgard Schambye, Jens Sigurd Okkels, Kim Vilbour Andersen, Torben Lauesgaard Nissen, Bobby Soni, Claus Bekker Jeppesen, Bart van den Hazel
-
Patent number: 6646110Abstract: The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at least one non-polypeptide moiety attached to an attachment group of the polypeptide. The attachment group may e.g., be a lysine, cysteine, aspartic acid or glutamic acid residue or a glycosylation site, and the non-polypeptide moiety may e.g., be a polymer such as polyethylene glycol or an oligosaccharide. The conjugate has one or more improved properties such as increased biological half-life and reduced side effects.Type: GrantFiled: January 10, 2001Date of Patent: November 11, 2003Assignee: Maxygen Holdings Ltd.Inventors: Torben Lauesgaard Nissen, Kim Vilbour Andersen, Christian Karsten Hansen, Jan Moller Mikkelsen, Hans Thalsgard Schambye
-
Publication number: 20030191038Abstract: The present invention relates to subtilase enzymes of the I-S1 and I-S2 sub-groups having an additional amino acid in the active site loop (c) region from positions 125 to 132. The variant subtilases of the present invention exhibit improved wash performance in a detergent in comparison to its parent enzyme.Type: ApplicationFiled: September 13, 2002Publication date: October 9, 2003Applicant: Novozymes A/SInventors: Peter Kamp Hansen, Peter Bauditz, Frank Mikkelsen, Kim Vilbour Andersen, Carsten Andersen, Mads Norregaard-Madsen
-
Publication number: 20030186386Abstract: Conjugates exhibiting IL-10 activity comprising (i) a polypeptide which comprises an amino acid sequence that differs from that of human IL-10 in at least one amino acid residue selected from an introduced or removed amino acid residue comprising an attachment group for the non-polypeptide moiety of (ii), and (ii) a non-polypeptide moiety. The conjugates have increased half-life as compared to hIL-10 and may be used for treatment of, e.g., inflammatory diseases.Type: ApplicationFiled: December 3, 2002Publication date: October 2, 2003Inventors: Christian Karsten Hansen, Kim Vilbour Andersen
-
Publication number: 20030175240Abstract: The present invention provides new interferon &bgr; conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.Type: ApplicationFiled: December 19, 2002Publication date: September 18, 2003Applicant: Maxygen ApSInventors: Anders Hjelholt Pedersen, Kim Vilbour Andersen, Claus Bornaes, Poul Baad Rasmussen
-
Publication number: 20030176328Abstract: The invention relates to a conjugate comprising an adiponectin polypeptide, and a first non-polypeptide moiety covalently attached to the adiponectin polypeptide, wherein the adiponectin polypeptide comprises an amino acid residue having an attachment group for said first non-polypeptide moiety, wherein said amino acid residue has been introduced in a position that in the parent adiponectin is occupied by a surface exposed amino acid residue.Type: ApplicationFiled: December 20, 2002Publication date: September 18, 2003Applicant: Maxygen ApSInventors: Poul Baad Rasmussen, Kim Vilbour Andersen, Anders Hjelholt Pedersen, Hans Thalsgaard Schambye, Torben Halkier, Are Bogsnes
-
Publication number: 20030175241Abstract: The present invention provides new interferon &bgr; conjugates, methods of preparing such conjugates and the use of such conjugates in therapy, in particular for the treatment of multiple sclerosis.Type: ApplicationFiled: January 24, 2003Publication date: September 18, 2003Applicant: Maxygen ApSInventors: Anders Hjelholt Pedersen, Hans Thalsgaard Schambye, Kim Vilbour Andersen, Claus Bornaes, Poul Baad Rasmussen
-
Publication number: 20030176304Abstract: The present invention relates to enzymes produced by mutating the genes for a number of subtilases and expressing the mutated genes in suitable hosts are presented. The enzymes exhibit improved wash performance in any detergent in comparison to their wild type parent enzymes.Type: ApplicationFiled: January 3, 2003Publication date: September 18, 2003Applicant: Novozymes A/SInventors: Peter Kamp Hansen, Peter Bauditz, Frank Mikkelsen, Kim Vilbour Andersen
-
Publication number: 20030170206Abstract: The invention relates to a conjugate exhibiting interferon &bgr; (IFNB) activity and comprising at least one first non-polypeptide moiety covalently attached to an IFNB polypeptide, the amino acid sequence of which differs from that of wildtype human IFNB in at least one introduced and at least one removed amino acid residue comprising an attachment group for said first non-polypeptide moiety. The first non-polypeptide moiety is e.g. a polymer molecule or a sugar moiety. The conjugate finds particular use in therapy. The invention also relates to a glycosylated variant of a parent IFNB polypeptide comprising at least one in vivo glycosylation site, wherein an amino acid residue of said parent polypeptide located close to said glycosylation site has been modified to obtain the variant polypeptide having an increased glycosylation as compared to the glycosylation of the parent polypeptide.Type: ApplicationFiled: February 26, 2002Publication date: September 11, 2003Applicant: Maxygen ApSInventors: Poul Baad Rasmussen, Joern Drustrup, Grethe Rasmussen, Anders Hjelholt Pedersen, Hans Thalsgard Schambye, Kim Vilbour Andersen, Claus Bornaes
-
Publication number: 20030171235Abstract: The present invention relates to subtilase enzymes of the I-S1 and I-S2 sub-groups having an additional amino acid in the active site loop (b) region from positions 95 to 103. The variant subtilases of the present invention exhibit improved wash performance in a detergent in comparison to its parent enzyme.Type: ApplicationFiled: September 12, 2002Publication date: September 11, 2003Applicant: Novozymes A/SInventors: Peter Kamp Hansen, Peter Bauditz, Frank Mikkelsen, Kim Vilbour Andersen, Carsten Andersen, Mads Norregaard-Madsen
-
Publication number: 20030165996Abstract: Methods for producing polypeptide with altered immunogenicity or improved stability properties are disclosed.Type: ApplicationFiled: July 3, 2002Publication date: September 4, 2003Inventors: Torben Halkier, Anders Hjelholt Pedersen, Jens Sigurd Okkels, Kim Vilbour Andersen
-
Publication number: 20030158375Abstract: The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at least one non-polypeptide moiety attached to an attachment group of the polypeptide. The attachment group may e.g. be a lysine, cysteine, aspartic acid or glutamic acid residue or a glycosylation site, and the non-polypeptide moiety may e.g. be a polymer such as polyethylene glycol or an oligosaccharide. The conjugate, which has a reduced in vitro bioactivity compared to hG-CSF, has one or more improved properties such as increased biological half-life and increased stimulation of neutrophils.Type: ApplicationFiled: December 13, 2002Publication date: August 21, 2003Applicant: Maxygen Holdings, Ltd.Inventors: Torben Lauesgaard Nissen, Kim Vilbour Andersen, Christian Karsten Hansen, Jan Moller Mikkelsen, Hans Thalsgaard Schambye
-
Publication number: 20030153046Abstract: A conjugate exhibiting interferon gamma activity and comprising at least one first non-polypeptide moiety covalently linked to an IFG polypeptide, the polypeptide comprising an amino acid sequence that differs from that of a parent IFNG polypeptide in at least one introduced and/or at least one removed amino acid residue comprising an attachment group for the non-polypeptide moiety. The conjugate may be used for treatment of various diseases.Type: ApplicationFiled: February 19, 2003Publication date: August 14, 2003Applicant: MaXygen Holdings, Ltd.Inventors: Anne Dam Jensen, Kim Vilbour Andersen, Christian Karsten Hansen